MedTrace Logo

Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT00129948 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 211

Last updated 2006-11-03

No results posted yet for this study

Summary

This is a phase 2, single-arm, open-label, multi-center study to establish the safety and efficacy of Troxatyl™ (troxacitabine) administered as a continuous infusion for 5 days to subjects with AML.

Conditions

  • Leukemia, Myeloid, Acute

Interventions

DRUG

Troxatyl™ (troxacitabine)

Sponsors & Collaborators

  • SGX Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Francis Giles, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Completion
2007-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00129948 on ClinicalTrials.gov